Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs
- PMID: 12425470
- DOI: 10.1023/a:1020412817716
Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs
Abstract
Purpose: [corrected] The purpose of this study was to design novel gastroretentive dosage forms (GRDFs) based on unfolding multilayer polymeric films, to investigate the mechanism of their gastroretentivity in dogs, and to assess the effect of compounding a narrow absorption window drug in a GRDF on the drug's absorption properties.
Methods: Dosage forms (DFs) with different dimensions and mechanical properties were administered to beagle dogs with acidic buffer (pH = 1.5), whose gastric retention time (GRT) was then determined by X-ray pictures. Concurrent administration of radiopaque markers was used to assess the effect of the GRDF and/or acidic buffer on GRT. The absorption of riboflavin from a prototype GRDF was compared with a nongastroretentive controlled-release DF and to an oral solution of the drug.
Results: Large DFs (> or = 2.5 x 2.5 cm) containing rigid frame had prolonged GRT (>4 h). Administration of 400 mL of acidic buffer (or water) prolonged GRT whereas the GRDF did not cause additional prolongation. The extended absorption phase (>48 h) of riboflavin administered in a GRDF led to 4-fold increased bioavailability.
Conclusion: The combination of large dimensions with rigidity produce gastroretentivity that can be used to improve absorption properties of a model of narrow absorption window drugs in the gastrointestinal tract.
Similar articles
-
Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans.Pharm Res. 2003 Sep;20(9):1466-73. doi: 10.1023/a:1025770530084. Pharm Res. 2003. PMID: 14567643 Clinical Trial.
-
Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs.J Control Release. 2003 Feb 14;88(1):117-26. doi: 10.1016/s0168-3659(02)00487-x. J Control Release. 2003. PMID: 12586509
-
Expandable gastroretentive dosage forms.J Control Release. 2003 Jun 24;90(2):143-62. doi: 10.1016/s0168-3659(03)00203-7. J Control Release. 2003. PMID: 12810298 Review.
-
Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans.J Control Release. 2006 Jul 20;113(3):208-15. doi: 10.1016/j.jconrel.2006.03.022. Epub 2006 Apr 26. J Control Release. 2006. PMID: 16806558 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.Int J Pharm. 2004 Jun 11;277(1-2):141-53. doi: 10.1016/j.ijpharm.2003.09.047. Int J Pharm. 2004. PMID: 15158977 Review.
Cited by
-
Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo.Sci Adv. 2020 Oct 28;6(44):eabb4133. doi: 10.1126/sciadv.abb4133. Print 2020 Oct. Sci Adv. 2020. PMID: 33115736 Free PMC article.
-
Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans.Pharm Res. 2003 Sep;20(9):1466-73. doi: 10.1023/a:1025770530084. Pharm Res. 2003. PMID: 14567643 Clinical Trial.
-
Swelling/floating capability and drug release characterizations of gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose.PLoS One. 2015 Jan 24;10(1):e0116914. doi: 10.1371/journal.pone.0116914. eCollection 2015. PLoS One. 2015. PMID: 25617891 Free PMC article.
-
Preparation and characterization of a gastric floating dosage form of capecitabine.Biomed Res Int. 2013;2013:495319. doi: 10.1155/2013/495319. Epub 2013 Oct 29. Biomed Res Int. 2013. PMID: 24288681 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous